These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 34452748

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
    Chen W, Zhong S, Shan B, Zhou S, Wu X, Yang H, Ye S.
    J Ovarian Res; 2020 Aug 08; 13(1):89. PubMed ID: 32771026
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
    Bai H, Sha G, Xiao M, Gao H, Cao D, Yang J, Chen J, Wang Y, Zhang Z, Shen K.
    Oncotarget; 2016 Mar 29; 7(13):15566-76. PubMed ID: 26863639
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
    Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S.
    Am J Pathol; 2003 Dec 29; 163(6):2503-12. PubMed ID: 14633622
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S, Okamoto A.
    BMC Cancer; 2014 Nov 03; 14():799. PubMed ID: 25366985
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan DSP, Huang RY.
    EBioMedicine; 2019 Dec 03; 50():203-210. PubMed ID: 31761620
    [Abstract] [Full Text] [Related]

  • 14. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B.
    BMC Cancer; 2014 Feb 11; 14():80. PubMed ID: 24512620
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S, Cheng X.
    J Ovarian Res; 2017 Feb 10; 10(1):9. PubMed ID: 28187748
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alternating Amaurosis Fugax in Trousseau Syndrome: A Case Report.
    Kunitake K, Inagaki R, Furukawa S, Kitagawa S, Oguchi H, Ito Y.
    J Stroke Cerebrovasc Dis; 2019 Jul 10; 28(7):e92-e94. PubMed ID: 31097325
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.